This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect weak segmental performance.
BD (BDX) Gears Up for Q2 Earnings: What's in the Offing?
by Zacks Equity Research
BD's (BDX) second-quarter fiscal 2021 results are likely to reflect strong year-over-year growth in revenues from assays in its Life Sciences segment.
Cerner (CERN) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Cerner's (CERN) first-quarter results are likely to reflect gains from strategic deals.
Merit Medical (MMSI) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Merit Medical (MMSI) benefits from growth in revenues at the Cardiovascular segment in Q1.
DaVita (DVA) Q1 Earnings Beat Estimates, Revenues Miss Mark
by Zacks Equity Research
DaVita's (DVA) net dialysis and related lab-patient service revenues rise in Q1.
XRAY vs. ALGN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
XRAY vs. ALGN: Which Stock Is the Better Value Option?
McKesson (MCK) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.
Omnicell (OMCL) Q1 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Omnicell's (OMCL) raises adjusted EPS guidance for 2021 , which buoys optimism.
AmerisourceBergen (ABC) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal second-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.
DexCom (DXCM) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) first-quarter results benefit from domestic and international revenue growth.
Teleflex (TFX) Beats on Q1 Earnings and Revenues, Raises View
by Zacks Equity Research
The acquisition of Z-Medica and an increase in sales of new products contribute to Teleflex's (TFX) revenue growth in Americas in Q1
Dentsply International (XRAY) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Dentsply (XRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
ABIOMED's (ABMD) international and U.S. Impella revenues improve in Q4.
Surmodics (SRDX) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Surmodics (SRDX) records higher revenues in both its core units in the fiscal second quarter.
CONMED (CNMD) Earnings and Revenue Surpass Estimates in Q1
by Zacks Equity Research
CONMED (CNMD) witnesses growth in revenues in both its segments during Q1.
LabCorp (LH) Q1 Earnings Surpass Estimates, View Raised
by Zacks Equity Research
LabCorp's (LH) raises 2021 guidance but projects significant sinking of COVID-related testing revenues.
Amedisys (AMED) Q1 Earnings Beat Estimates, 2021 View Up
by Zacks Equity Research
Amedisys' (AMED) first-quarter 2021 revenues improves year over year on solid growth in the Home Health and Hospice divisions.
OPKO Health (OPK) Q1 Earnings Match Estimates, Revenues Top
by Zacks Equity Research
OPKO Health's (OPK) first-quarter results benefit from strength in diagnostics.
Integra (IART) Q1 Earnings Beat Estimates, Gross Margin Down
by Zacks Equity Research
Integra's (IART) first-quarter revenues improved year over year on organic growth across Codman Specialty Surgical and Tissue Technologies segments.
Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter's (BAX) first-quarter results reflect robust performance across five of its business units.
Chemed (CHE) Q1 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
Chemed's (CHE) first-quarter 2021 revenues increase year-over-year on solid growth across its Roto-Rooter arm.
Accuray (ARAY) Posts Breakeven Q3 Earnings, Beats on Revenues
by Zacks Equity Research
Accuray (ARAY) registers growth in Service and Product revenues during fiscal Q3.
Owens & Minor (OMI) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Owens & Minor (OMI) witnesses rebound in demand for elective procedures through the months of Q1.
Boston Scientific (BSX) Q1 Earnings Beat, Organic Sales Up
by Zacks Equity Research
Boston Scientific (BSX) registers strong sequential improvement in overall financial performance in Q1.
Stryker (SYK) Earnings and Revenues Miss Estimates in Q1
by Zacks Equity Research
Stryker's (SYK) first-quarter earnings reflect strong performance across Orthopaedics and Neurotechnology and Spine segments.